問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Digestive System Department

Division of Hematology & Oncology

Division of General Internal Medicine

國立臺灣大學醫學院

Division of General Internal Medicine

更新時間：2023-09-19

陳培哲CHEN, PEI-JER
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years

Recruiting Trial

21Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳培哲

List

102Cases

2020-02-01 - 2021-01-31

Phase I

A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EDP 514 in Healthy Subjects (Part 1), and Antiviral Activity in Nucleos(t)Ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients With Chronic Hepatitis B Virus Infection (Part 2)

  • Condition/Disease

    Chronic hepatitis B virus (CHB) infection

  • Test Drug

    EDP 514

Participate Sites
10Sites

Recruiting3Sites

Terminated7Sites

2011-06-01 - 2014-12-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2015-02-01 - 2017-06-30

Phase II

A MULTIPLE-CENTER, RANDOMIZED, PARTIALLY DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTIVIRAL EFFECTS OF 12-WEEK TREATMENT WITH RO6864018 IN VIROLOGICALLY SUPPRESSED ENTECAVIR TREATED PATIENTS WITH HEPATITIS B VIRUS INFECTION

  • Condition/Disease

    HEPATITIS B VIRUS(HBV) INFECTION

  • Test Drug

    RO6864018

Participate Sites
2Sites

Terminated2Sites

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2016-08-01 - 2019-04-15

Phase II

A Phase 2, Open-Label, Randomized Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected with Chronic Hepatitis B Virus

  • Condition/Disease

    HBV

  • Test Drug

    SB 9200

Participate Sites
5Sites

Terminated5Sites

2015-09-01 - 2016-07-31

Phase III

A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2)

  • Condition/Disease

    Chronic Liver Disease (CLD)

  • Test Drug

    S-888711

Participate Sites
3Sites

Terminated2Sites

2015-08-01 - 2017-12-31

Phase I

Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study To evaluate The Safety, Tolerability, And Immunogenicity Of INO-1800 Alone Or in Combination With INO-9112 Delivered IM Followed By Electroporation In Select Nucleos(t)ide Analogue-Treated, HBeAG-Positive, Chronic Hepatitis B Patients

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    INO-1800 and INO-9112

Participate Sites
6Sites

Terminated5Sites

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

莊萬龍
Kaohsiung Municipal Gangshan Hospital

未分科

2020-10-01 - 2023-06-05

Phase II

A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    ABI-H2158

Participate Sites
5Sites

Not yet recruiting5Sites

2016-10-31 - 2018-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2016-07-01 - 2020-01-31

Others

A randomized, double-blind, placebo controlled, 2- part, adaptive design, multicenter 12-week study to assess safety, tolerability and efficacy of LJN452 in patients with non-alcoholic steatohepatitis (NASH)

  • Condition/Disease

    non-alcoholic steatohepatitis (NASH)

  • Test Drug

    LJN452 (tropifexor)

Participate Sites
8Sites

Terminated6Sites

黃志富
Kaohsiung Municipal Gangshan Hospital

未分科

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2011-06-15 - 2013-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

1 6 7 8 9 10 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB